<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01151592</url>
  </required_header>
  <id_info>
    <org_study_id>1VEN10034</org_study_id>
    <nct_id>NCT01151592</nct_id>
  </id_info>
  <brief_title>Safety Assessment of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)</brief_title>
  <acronym>ASSURED</acronym>
  <official_title>Assessment of Safety of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luitpold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luitpold Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety and tolerability of Venofer in patients
      with chronic kidney disease who cannot tolerate Ferumoxytol (Feraheme) or intravenous iron
      containing a dextran (INFed or Dexferrum).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase IV, multi-center, open label study that assesses the safety and tolerability
      of Iron Sucrose (Venofer) in subjects with CKD who require intravenous iron for the treatment
      of iron deficiency anemia (IDA) but cannot tolerate Ferumoxytol or Iron Dextran.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor Decision
  </why_stopped>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events, overall and related from Day of first iron sucrose administration through the end of the study.</measure>
    <time_frame>Day 0 through 30 days after the final administration of iron sucrose</time_frame>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Sucrose</intervention_name>
    <description>Iron Sucrose, 1000 mg cumulative dose to be administered per the US package insert.</description>
    <other_name>Venofer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects &gt; or = to 18 years of age

          -  Determined by treating physician to have chronic kidney disease and require a course
             of intravenous iron

          -  Subject did not tolerate an intravenous iron containing a dextran or Ferumoxytol
             within the last year

          -  Subjects with hemodialysis-dependent or peritoneal dialysis chronic kidney disease
             should be receiving an erythropoiesis stimulating agent (ESA) as per the iron sucrose
             package insert

        Exclusion Criteria:

          -  Known history of hypersensitivity or significant intolerance to iron sucrose

          -  Evidence of iron overload

          -  Hemochromatosis or other iron storage disorders

          -  Received an investigational drug within 30 days of screening

          -  Any other laboratory abnormality, medical condition or psychiatric disorder which
             would put the subject's disease management at risk or may result in the subject being
             unable to comply with study requirements

          -  Pregnant or sexually-active female subjects who are of childbearing potential and who
             are not willing to use an acceptable form of contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Luitpold Pharmaceuticals, Inc.</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <zip>19403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2010</study_first_submitted>
  <study_first_submitted_qc>June 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2010</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iron deficiency anemia in Chronic Kidney Disease Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric oxide, saccharated</mesh_term>
    <mesh_term>Ferrosoferric Oxide</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
    <mesh_term>Iron-Dextran Complex</mesh_term>
    <mesh_term>Dextrans</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

